Pelican Acquisition's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Pelican Acquisition (PELIU) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
API endpoints for this dataset
Pelican Acquisition's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Pelican Acquisition Corporation | - | - | - | Yes |
| High-Confidence Competitors (35) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
PELIU Stock Performance relative to its Competitors
PELIU Stock Performance relative to High-Confidence Competitors
Pelican Acquisition's Comment on Competition and Industry Peers
Pelican Acquisition's Competitors Named by the Company
Competitive relationships identified from Pelican Acquisition reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Medpace Holdings Inc | Company report | 85% |
| Quanterix Corporation | Company report | 85% |
| Agilent Technologies inc | Company report | 85% |
| Twist Bioscience Corporation | Company report | 85% |
| Cytek Biosciences Inc | Company report | 85% |
| Ingersoll Rand Inc | Company report | 85% |
| Quidelortho Corp | Company report | 85% |
| Azenta Inc | Company report | 85% |
| Guardant Health Inc | Company report | 85% |
| Atlantic International Corp | Company report | 85% |
| Icon Plc | Company report | 85% |
| Iqvia Holdings Inc | Company report | 85% |
| Dlh Holdings Corp | Company report | 85% |
| Genetic Technologies Limited | Company report | 85% |
| Palisade Bio Inc | Company report | 85% |
| Greenland Exploration Limited | Company report | 85% |
| March GL Company | Company report | 85% |
| Waters Corporation | Company report | 85% |
| Mirion Technologies Inc | Company report | 85% |
| Galera Therapeutics Inc | Company report | 85% |
| 908 Devices inc | Company report | 85% |
| Quantum si Incorporated | Company report | 85% |
| Maxcyte inc | Company report | 85% |
| Sophia Genetics Sa | Company report | 85% |
| Volitionrx Limited | Company report | 85% |
| Nautilus Biotechnology Inc | Company report | 85% |
| Yeti Holdings Inc | Company report | 85% |
| Societal Cdmo Inc | Company report | 85% |
| Singular Genomics Systems Inc | Company report | 85% |
| Telesis Bio Inc | Company report | 85% |
| Caredx Inc | Company report | 85% |
| SQL | Company report | 85% |
| Emergent Biosolutions Inc | Company report | 85% |
| Auburn National Bancorporation Inc | Company report | 85% |
| Accelerate Diagnostics Inc | Company report | 85% |
| Idex Corp | Company report | 85% |
| WEED, INC. | Company report | 85% |
| Bio techne Corp | Company report | 85% |
| Us Nuclear Corp | Company report | 85% |
| Harvard Bioscience Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Pelican Acquisition's named competitors require a Commercial License.
Methodology: relationships are extracted from Pelican Acquisition reports (named-competitor disclosures) and corroborating sources. Confidence reflects evidence strength.